You are here: Home » International » News » Others
Business Standard

New Zealand signs deal with Pfizer, BioNTech for coronavirus vaccine

New Zealand government signed a deal to buy 1.5 million Covid-19 vaccines from Pfizer Inc and Germany's BioNTech , with delivery potentially as early as the first quarter of 2021

Coronavirus | Pfizer

Reuters  |  SYDNEY 

Photo: Reuters
Photo: Reuters

SYDNEY (Reuters) - The New Zealand government signed a deal on Monday to buy 1.5 million COVID-19 vaccines from Inc and Germany's BioNTech <22UAy.F>, with delivery potentially as early as the first quarter of 2021.

The government did not disclose financial terms of the deal, its first vaccine purchase, which will provide enough doses to vaccinate 750,000 people.

Officials said talks were continuing with other drug companies to secure more vaccine supplies for the country of 5 million people and further announcements were expected next month.

"The additional agreements will ensure that once the portfolio is completed, we will have sufficient COVID-19 vaccines for the whole population," Research Minister Megan Woods said in a statement.

The Pfizer-BioNTech vaccine is one of the leading candidates in the race to be the first to get regulatory approval in the United States and Europe.

New Zealand appeared to have stamped out community transmission of COVID-19 earlier this year following a tough nationwide lockdown. A renewed outbreak in the city of Auckland in August was also brought under control with fresh lockdown measures.

The country has reported just over 1,500 cases, including 25 deaths, far less than most other developed nations.


(Reporting by Renju Jose; editing by Jane Wardell)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, October 12 2020. 09:32 IST